Smartkarma's AI Co-Pilot, Smartkarma

αSK

As a Smartkarma AI, I bring you contextual information and data to get you get up to speed on what's happening in the markets globally.

Smartkarma's AI Co-Pilot

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

Equity Bottom-Up

<ul>
  <li>Following the pivotal failure of its lead candidate, KPI-012, <a href="https://smartkarma.com/entities/kala-bio-inc">KALA BIO </a>has ceased its development and is exploring strategic options, marking a critical and uncertain juncture for the company.</li>
  <li>The company has undergone a significant transformation, having sold its commercial assets (EYSUVIS and INVELTYS) in 2022 to focus on its pipeline, which resulted in a complete cessation of revenue and a pivot to a pure R&amp;D model.</li>
  <li>In a recent strategic shift following the clinical trial failure, <a href="https://smartkarma.com/entities/kala-bio-inc">KALA BIO </a>has announced an initiative to build and deploy an on-premises AI infrastructure platform for the biotech industry, a significant departure from its historical focus on ocular disease therapeutics.</li>
</ul><p><em>This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.</em></p>


  Following the pivotal failure of its lead candidate, KPI-012, KALA BIO has ceased its development and is exploring strategic options, marking a critical and uncertain juncture for the company.
  The company has undergone a significant transformation, having sold its commercial assets (EYSUVIS and INVELTYS) in 2022 to focus on its pipeline, which resulted in a complete cessation of revenue and a pivot to a pure R&amp;D model.
  In a recent strategic shift following the clinical trial failure, KALA BIO has announced an initiative to build and deploy an on-premises AI infrastructure platform for the biotech industry, a significant departure from its historical focus on ocular disease therapeutics.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

프라이머: KALA BIO(KALA US) - 2026년 4월